Transgender research papers: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
===Masculinization=== | ===Masculinization=== | ||
====Hormone replacement therapy==== | |||
* [https://pubmed.ncbi.nlm.nih.gov/32298661/ (April 2020) Testosterone, Cortisol, and Secretory immunoglobulin-A Within a Single Day and Across Two Sequential Days Among Trans- And Cis-Gender Men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/32105330 (March 2020) Impact of Exogenous Testosterone on Reproduction in Transgender Men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/32044312 (February 2020) The effect of testosterone on ovulatory function in transmasculine individuals.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/31585007 (October 2019) A mouse model to investigate the impact of testosterone therapy on reproduction in transgender men.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676071/ (August 2019) Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/30999214 (June 2019) The effect of testosterone therapy on personality traits of trans men: a controlled prospective study in Germany and Switzerland.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/30987859 (April 2019) Longitudinal Case Study of Transgender Voice Changes Under Testosterone Hormone Therapy.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/30025172 (July 2018) Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration.]* | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/29908619 (July 2018) Hormone Therapy for Transgender Men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/29624102 (June 2018) Exogenous Testosterone Does Not Induce Or Exacerbate The Metabolic Features Associated With PCOS Among Transgender Men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/29913543 (May 2018) Recommendations for the Use of Testosterone in Male Transgender.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/29367424 (March 2018) Pharmacokinetics, safety, and patient acceptability of subcutaneous versus intramuscular testosterone injection for gender-affirming therapy: A pilot study.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796953/ (February 2018) Severe Secondary Polycythemia in a Female-to-Male Transgender Patient While Using Lifelong Hormonal Therapy: A Patient’s Perspective.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/28765273 (November 2017) Cross-sex testosterone therapy in ovariectomized mice: addition of low-dose estrogen preserves bone architecture.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/29145707 (November 2017) Relationship between testosterone in serum, saliva and urine during treatment with intramuscular testosterone undecanoate in gender dysphoria and male hypogonadism.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685207/ (October 2017) The Response of the Menstrual Cycle to Initiation of Hormonal Therapy in Transgender Men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/28709177 (September 2017) Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/28379417 (July 2017) Subcutaneous Injection of Testosterone Is an Effective and Preferred Alternative to Intramuscular Injection: Demonstration in Female-to-Male Transgender Patients.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/27084565 (April 2017) Testosterone therapy for transgender men.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/28159147 (March 2017) Hormonal and Surgical Treatment Options for Transgender Men (Female-to-Male).] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4754845/ (February 2016) Consecutive lynestrenol and cross-sex hormone treatment in biological female adolescents with gender dysphoria: a retrospective analysis.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4585531 (October 2015) High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/25772768 (May 2015) Antimüllerian hormone levels decrease in female-to-male transsexuals using testosterone as cross-sex therapy.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/25111431 (February 2015) Testosterone treatment and MMPI-2 improvement in transgender men: a prospective controlled study.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/24047564 (September 2013) Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/23117148 (October 2012) Dose-response analysis of testosterone replacement therapy in patients with female to male gender identity disorder.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256750/ (January 2012) Associations between transition-specific stress experience, nocturnal decline in ambulatory blood pressure, and C-reactive protein levels among transgender men.] | |||
* [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2913672/ (March 2010) Alterations in Lipids and Adipocyte Hormones in Female-to-Male Transsexuals.] | |||
* [https://www.ncbi.nlm.nih.gov/pubmed/19749027 (September 2009) Safety aspects of 36 months of administration of long-acting intramuscular testosterone undecanoate for treatment of female-to-male transgender individuals.] |